Effect of eNOS and ET-1 polymorphisms in thromboangiitis obliterans

Clinical and Applied Thrombosis/Hemostasis

Volumn 16, Issue 1, 2010, Pages 103-106

  Adigüzel, Yekbun ^a   Yilmaz, Erkan ^b   Akar, Nejat ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Endothelin 1; ENOS; Thromboangiitis obliterans (Buerger disease)

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1;

ADULT; ALLELE; ARTICLE; BUERGER DISEASE; CONTROLLED STUDY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; SMOKING CESSATION;

ADULT; ENDOTHELIN-1; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; NITRIC OXIDE SYNTHASE TYPE III; POLYMORPHISM, GENETIC; PREVALENCE; RISK FACTORS; SMOKING; THROMBOANGIITIS OBLITERANS; YOUNG ADULT;

EID: 76049101637     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029609336854     Document Type: Article

References (14)

1. Buerger L. Landmark publication from the American Journal of the Medical Sciences: Thromboangiitis obliterans: A study of vascular lesions leading to presenile spontaneous gangrene, 1908. Am J Med Sci 2009 ; 337 (4). 274-284.
2. Joyce JW Buergergs disease (thromboangiitis obliterans). Rheum Dis Clin North Am. 1990 ; 16 (2). 463-470.
3. Fitridge R, Thompson M, eds. Mechanisms of Vascular Disease: A Textbook for Vascular Surgeons. Cambridge: Cambridge University Press ; 2007.
4. Monacada S., Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993 ; 329 (27). 2002-2012.
5. Avcu F., Akar E., Demirkiliĉ U., Yilmaz E., Akar N., Yalĉin A. The role of prothrombotic mutations in patients with Buergergs Disease. Thromb Res. 2000 ; 100 (3). 143-147.
6. Hingorani AD, Liang CF, Fatibene J., et al. A common variant of the endothelial nitric oxide synthase (Glu298g→Asp) is a major risk factor for coronary artery disease in the UK. Circulation. 1999 ; 100 (14). 1515-1520.
7. Glueck CJ, Haque M., Winarska M., et al. Stromelysin-1 5A/6A and eNOS T-786C polymorphisms, MTHFR C677T and A1298C mutations, and cigarette-cannabis smoking: a pilot, hypothesis-generating study of gene-environment pathophysiological associations with Buergergs Disease. Clin Appl Thromb Hemost. 2006 ; 12 (4). 427-439.
8. Czarnacki M., Gacka M., Adamiec R. A role of endothelin 1 in the pathogenesis of thromboangiitis obliterans (initital news). Przegl Lek. 2004 ; 61 (12). 1346-1350.
9. Mozes M., Cahansky G., Doitsch V., Adar R. The association of atherosclerosis and Buergergs disease: a clinical and radiological study. J Cardiovasc Surg. 1970 ; 11 (1). 52-59.
10. Akar N., Akar E., Yilmaz E. Factor V (His 1299 Arg) in Turkish patients with venous thrombo embolism. Am J Hematol. 2000 ; 63 (2). 102-103. (Pubitemid 30068920)
11. Akar N., Misirlioǧlu M., Akar E., Avcu F., Yalĉin A., Sözüöz A. Prothrombin gene 20210 Gg→A mutation in the Turkish population. Am J Hematol. 1998 ; 58 (3). 249.
12. Akar N., Akar E., Dalgin G., Sözüöz A., Ömürlü K., Cin Ş. Frequency of factor V (1691 Gg→A) mutation in Turkish population. Thromb Haemost. 1997 ; 78 (6). 1527-1528.
13. Avcu F., Akar N., Akar E., Beyan C., Yalĉin A. Prothrombin gene 20210 Gg→A and Factor V Arg 506 to Gln mutation in a patient with Buergergs Disease-a case report. Angiology. 2000 ; 51 (5). 421-423.
14. Adar R., Papa MZ, Halpern Z., et al. Cellular sensitivity to collagen in thromboangiitis obliterans. N Engl J Med. 1983 ; 308: 1113-1116.